GLP-1 analogs appear to exert their anti-obesity effects through central pathways that do not involve MC4R, as well as via peripheral mechanisms involving the vagus nerve, they wrote
For sensitive research material, that patience is the whole point
Diabetes 51:712717 Anno T, Uehara S, Katagiri H et al (2004) Overexpression of constitutively activated glutamate dehydrogenase induces insulin secretion through enhanced glutamate oxidation
Different mechanisms (Cu-signaling vs SNAP-25-mimetic)
Multiple cardiovascular outcome trials (ELIXAlixisenatide, LEADERliraglutide, SUSTAIN-6semaglutide, EXSCELexenatide, Harmony Outcomesalbiglutide, REWINDdulaglutide, and PIONEER-6oral semaglutide) have reported, to a greater or lesser extent, improvements in cardiovascular outcomes, with a systematic review and meta-analysis of these trials involving a combined total of 56,004 participants showing that these drugs as a class reduced major adverse cardiovascular events by 12%, death from cardiovascular causes by 12%, fatal or nonfatal stroke by 16%, and fatal or nonfatal myocardial infarction by 9%